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Duchenne muscular dystrophy (DMD) is a devastating disease affecting about 1 out of 5000 male 
births and caused by mutations in the dystrophin gene. Genome editing has the potential to restore 
expression of a modified dystrophin gene from the native locus to modulate disease progression. 
In this study, adeno-associated virus was used to deliver the CRISPR/Cas9 system to the mdx 
mouse model of DMD to remove the mutated exon 23 from the dystrophin gene. This includes 
local and systemic delivery to adult mice and systemic delivery to neonatal mice. Exon 23 deletion 
by CRISPR/Cas9 resulted in expression of the modified dystrophin gene, partial recovery of 
functional dystrophin protein in skeletal myofibers and cardiac muscle, improvement of muscle 
biochemistry, and significant enhancement of muscle force. This work establishes CRISPR/Cas9-
based genome editing as a potential therapy to treat DMD.
Duchenne muscular dystrophy (DMD) is among the most prevalent fatal genetic diseases, 
occurring in 1 out of 5000 male births (1). It results in muscle degeneration, loss of mobility, 
and premature fatality. DMD mutations are often deletions of one or more exons in the 
dystrophin gene that disrupt the reading frame of the gene and lead to a complete loss of 
functional dystrophin expression. In contrast, Becker muscular dystrophy (BMD) is 
associated with much milder symptoms relative to DMD and is caused by internal, in-frame 
deletions of the dystrophin gene resulting in expression of a truncated but partially 
functional dystrophin protein (2). Because of the genetic nature of the disease, gene therapy 
is a promising option to treat DMD. However, the very large size of the dystrophin cDNA 
presents a challenge to gene delivery. Consequently, some therapeutic strategies aim to 
generate a BMD-like dystrophin. These approaches include the development of mini/micro-
dystrophin genes for delivery by adeno-associated virus (AAV) vectors (3-6) and 
oligonucleotide-mediated exon skipping therapies designed to restore the reading frame of 
the transcript (7, 8). For example, removal of exon 51 can address 13% of DMD patient 
mutations, and exon skipping strategies could be extended to other regions of the gene to 
collectively treat 83% of DMD patients (9). In contrast, genome editing technologies can be 
used to directly correct disease-causing genetic mutations (10) and may be a preferred 
approach for a single treatment to restore stable expression of a dystrophin protein that 
contains most of the normal structure and function and is also under physiologic control of 
the natural promoter. In particular, the CRISPR/Cas9 genome editing system, which uses the 
Cas9 nuclease to cleave DNA sequences targeted by a single guide RNA (gRNA) (11), has 
recently created new possibilities for gene therapy by making precise genome modifications 
possible in cultured cells (12-15) and in animal studies (16-19). Analogous to exon-skipping 
therapies, CRISPR-mediated removal of one or more exons from the genomic DNA could be 
applied to the treatment of 83% of DMD patients. Moreover, this approach can be easily 
extended to targeting multiple exons within mutational hotspots, such as the deletion of 
exons 45-55 that could address 62% of DMD patients with a single gene editing strategy 
(20). We and others have applied these tools to correct dystrophin mutations in cultured 
human cells from DMD patients (20-25) and in mdx mouse embryos (26). A critical 
remaining challenge is to translate these proof-of-principle results into a clinically relevant 
approach for genome editing in muscle tissue in vivo. The use of genome editing for exon 
removal, rather than replacing missing exons to restore a full-length gene, may be desirable 
for several reasons. Editing by exon removal takes advantage of the relatively efficient non-
homologous end joining pathway that is active in all cell types, in contrast to targeted gene 
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addition by the homology-directed repair pathway that is downregulated in post-mitotic cells 
such as skeletal myocytes and myofibers. This method also avoids the need to deliver a DNA 
repair template. Finally, gene editing to delete exons will be more applicable to large patient 
populations that include a variety of mutations, in contrast to patient-specific editing 
strategies that restore unique gene deletions.
The mdx mouse model of DMD has a nonsense mutation in exon 23, which prematurely 
terminates protein production (27). Removal of exon 23 from the transcript through 
oligonucleotide-mediated exon skipping restores functional dystrophin expression and 
improves muscle contractility (28, 29). Here, we have developed an AAV-based strategy for 
the treatment of DMD in the mdx mouse by harnessing the unique multiplexing capacity of 
CRISPR/Cas9 to excise exon 23 from the dystrophin gene. We hypothesized that CRISPR-
mediated removal of exon 23 from the genomic DNA would restore dystrophin expression 
and improve muscle function (Fig. 1a).
We used AAV serotype 8 (AAV8) as a vector for delivery and expression of the components 
of the CRISPR/Cas9 system to skeletal and cardiac muscle (30). Due to the packaging size 
restrictions of AAV (~4.7 kb), we utilized the 3.2 kb Staphylococcus aureus Cas9 (SaCas9) 
cDNA that was recently described for in vivo genome editing applications (19). A second 
AAV vector with two guide RNA (gRNA) expression cassettes was also produced to express 
gRNAs targeted to introns 22 and 23. We expected that simultaneous DNA cleavage in both 
introns by Cas9/gRNA complexes would remove exon 23 from the genome and result in 
production of an internally truncated, but highly functional, dystrophin protein. A panel of 
gRNAs was designed by manual inspection for the SaCas9 PAM (5’-NNGRRT-3’) with 
close proximity to exon 23 and prioritized according to predicted specificity by minimizing 
potential off-target sites in the mouse genome. The best set of gRNAs was then selected 
based on in vitro gene editing efficiency (Fig. S1).
The Cas9 and gRNA AAV vectors were premixed in equal amounts and injected into the 
tibialis anterior muscle of mdx mice. Contralateral limbs received saline injection. At eight 
weeks post-injection, the muscles were harvested and analyzed for deletion of exon 23 from 
the genomic DNA and mRNA, and expression of dystrophin protein. End-point PCR across 
the genomic locus revealed the expected ~1,171 bp deletion in all injected limbs (Fig. 1b). 
Droplet digital PCR (ddPCR) was used to quantify the percent of modified alleles by 
separately amplifying the unmodified or deleted DNA templates. ddPCR showed that exon 
23 was deleted in ~2% of all alleles from the whole muscle lysate (Fig. 1c). Sanger 
sequencing of gel-extracted bands confirmed the deletion of exon 23 as predicted without 
any additional indels (Fig. 1b). Deep sequencing of these amplicons indicated a strong 
preference (~66%) for precise ligation of cut products (Fig. S2). Regardless, the distribution 
of indels in the deletion should not impact transcript production as the indels occur in the 
intronic region. Deep sequencing of gRNA target sites and the top 10 predicted off-target 
sites for each gRNA indicated ~3% indel formation at the target sites and low (~1%, 
gRNA1-OT8) or undetectable off-target gene editing at the predicted off-target sites (Table 
S2-S3, Fig. S3).
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RT-PCR of mRNA extracted from muscle lysates showed a fraction of transcripts without 
exon 23 (Fig. 1d). Quantitative ddPCR of the cDNA also showed significant editing of the 
mRNA transcript with exon 23 excluded in 59% of transcripts (Fig. 1e). The high frequency 
of mRNA modification is likely due to protection of the Δ23 transcripts from nonsense-
mediated decay. This is supported by an increase in total dystrophin mRNA from 5% of 
wild-type mRNA levels in non-treated muscles to 12% in Cas9/gRNA-treated muscles (Fig. 
S4).
Western blot of whole muscle lysates showed substantial recovery of dystrophin protein to 
~8% of the normal level (Fig. 2a). By immunostaining, ~67% of myofibers expressed 
dystrophin (Fig. 2b, Fig. 3a). Immunofluorescence staining also confirmed Cas9 expression 
in myonuclei (Fig. S5). Collectively, the molecular analyses of genomic deletion, exon 
removal from the transcript, and abundant protein expression validated CRISPR-mediated 
restoration of a near-full length dystrophin protein to levels above the established 
benchmarks for functional recovery and therapeutic benefit. In particular, it is reported that 
as little as 4% of normal dystrophin expression level is sufficient to improve muscle function 
(31, 32), and human natural history studies show that 30% protein expression may be 
sufficient for a completely asymptomatic phenotype (33). Therefore we evaluated 
therapeutic benefit in CRISPR-treated mdx mice. We first examined sarcolemmal neuronal 
nitric oxide synthase (nNOS) localization. nNOS is absent in the sarcolemma of the mdx 
mouse and DMD patients due to the loss of the nNOS-binding site in spectrin repeats 16 and 
17 in the dystrophin protein (34, 35). The mislocalization of nNOS contributes to DMD 
pathogenesis (34, 35). In CRISPR-treated muscles, nNOS activity was restored at the 
sarcolemma closely mirroring dystrophin staining in serial sections (Fig. 3a-b) and 
resembling that of wild-type muscle (Fig. S6).
Dystrophin assembles a series of transmembrane and cytosolic proteins into the dystrophin-
associated glycoprotein complex (DGC) to link the cytoskeleton and the extracellular matrix 
(1). In mdx mice and DMD patients, these proteins are mislocalized. Immunostaining of 
serial muscle sections showed recovery of DGC proteins in Cas9/gRNA-treated muscles, but 
not the contralateral controls (Fig. S7-S9). Histological examination showed improved 
overall morphology of CRISPR/Cas9-treated muscles, including reduced fibrosis (Fig. 3c, 
Fig. S10). The number of infiltrating macrophages and neutrophils was substantially 
decreased in treated muscle, indicating a reduction of the inflammation typical of dystrophic 
muscle (Fig. S11). Hematoxylin and eosin staining of serial sections showed no obvious 
response to the vector or transgene in this study (Fig. 3c). However, potential immune 
responses to the AAV capsid, Cas9, and dystrophin are important subjects for future studies 
(6, 36-38).
Next, we assessed muscle function. The specific twitch (Pt) and tetanic (Po) force were 
significantly improved in Cas9/gRNA-treated muscle (*p<0.05, Fig. 3d). Treated muscles 
showed significantly improved resistance to eccentric contraction injury, maintaining 50% of 
the initial force relative to 37% in untreated muscle (*p<0.05 at marked cycles, Fig. 3d). 
Further, pathologic hypertrophy was mitigated in Cas9/gRNA-treated muscle (Table S4). 
Collectively these results show that CRISPR/Cas9-mediated dystrophin restoration improved 
muscle structure and function.
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To assess the effects of dystrophin restoration early in life, we performed intraperitoneal 
injections of the AAV vector into P2 neonatal mice. This led to recovered dystrophin 
expression in abdominal muscles, diaphragm, and heart at seven weeks post-injection (Fig. 
S12-S13). Importantly, these muscles are responsible for cardiac and pulmonary health, 
which are severely weakened and responsible for the premature death of DMD patients. 
Finally, intravenous administration of AAV vectors in six-week-old adult mdx showed 
significant recovery of dystrophin in the cardiac muscle (Fig. 4). Efficient cardiac correction 
will be a significant end-point to prevent premature death of DMD patients.
In this study we have demonstrated the therapeutic benefit of AAV-mediated CRISPR/Cas9 
genome editing in an adult mouse model of DMD. Our results include correction in a single 
muscle following local delivery and in the heart following intravenous delivery to neonatal 
and adult mice. As systemic delivery of AAV vectors to skeletal and cardiac tissue is well-
established, we expect this approach to confer body-wide therapeutic benefits. The 
accompanying article from Wagers and colleagues (39) uses a similar approach to CRISPR/
Cas9-based correction of dystrophic mice using delivery with AAV9, demonstrating 
generality across muscle-tropic AAV serotypes. Moreover, their demonstration of efficient 
editing of Pax7-positive muscle satellite cells (39) suggests that gene correction may 
improve as the mature muscle fibers are populated with the progeny of these progenitor 
cells, as was observed in mosaic mice generated by CRISPR/Cas9 delivery to single cell 
zygotes (26). In fact, we have observed that dystrophin restoration by genome editing is 
maintained for at least six months post-treatment (Fig. S14).
Continued optimization of vector design will be important for potential clinical translation 
of this approach, including evaluation of various AAV capsids and tissue-specific promoters. 
Additionally, although dual vector administration has been effective in body-wide correction 
of animal models of DMD (40), optimization to engineer a single vector approach may 
increase efficacy and translatability. These two studies (39) establish a strategy for gene 
correction by a single gene editing treatment that has the potential to achieve similar effects 
as seen with weekly administration of exon skipping therapies (7, 8, 28, 29). More broadly, 
this work establishes CRISPR/Cas9-mediated genome editing as an effective tool for gene 
modification in skeletal and cardiac muscle and as a therapeutic approach to correct protein 
deficiencies in neuromuscular disorders and potentially many other diseases. The continued 
developed of this technology to characterize and enhance the safety and efficacy of gene 
editing will help to realize its promise for treating genetic disease.
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Figure 1. CRISPR/Cas9-mediated genomic and transcript deletion of exon 23 through 
intramuscular AAV-CRISPR administration
(a) The Cas9 nuclease is targeted to introns 22 and 23 by two gRNAs. Simultaneous 
generation of double stranded breaks (DSBs) by Cas9 leads to excision of the region 
surrounding the mutated exon 23. The distal ends are repaired through non-homologous end 
joining (NHEJ). The reading frame of the dystrophin gene is recovered and protein 
expression is restored. (b) PCR across the genomic deletion region shows the smaller 
deletion PCR product in treated muscles. Sequencing of the deletion band shows perfect 
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ligation of Cas9 target sites (+, AAV-injected muscles; −, contralateral muscles). (c) ddPCR 
of deletion products shows 2% genome editing efficiency (n=6, mean+s.e.m.). (d) RT-PCR 
across exons 22 and 24 of dystrophin cDNA shows a smaller band that does not include 
exon 23 in treated muscles. Sanger sequencing confirmed exon 23 deletion. (e) ddPCR of 
intact dystrophin transcripts and Δ23 transcripts shows 59% of transcripts do not have exon 
23 (n=6, mean+s.e.m.). bGHpA, bovine growth hormone polyadenylation sequence; ITR, 
inverted terminal repeat; NLS, nuclear localization signal. Asterisk, significantly different 
from the sham group (p<0.05).
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Figure 2. In vivo genome editing restores dystrophin protein expression
(a) Western blot for dystrophin shows recovery of dystrophin expression (+, AAV-injected 
muscle; −, contralateral muscle). Comparison to protein from wild-type (WT) mice indicates 
restored dystrophin is ~8% of normal levels (n=6, mean+s.e.m.). (b) Dystrophin 
immunofluorescence staining shows abundant (67%) dystrophin-positive fibers in Cas9/
gRNA treated groups (scale bar = 100 μm, n=7, mean+s.e.m.). Asterisk, significantly 
different from the sham group (p<0.05).
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Figure 3. CRISPR/Cas9 gene editing restores nNOS activity and improves muscle function
(a) Whole muscle transverse sections show abundant dystrophin expression throughout the 
tibialis anterior muscle. (b) Staining of serial sections shows recruitment and activity of 
nNOS in a pattern similar to dystrophin expression. (c) H&E staining shows no obvious 
adverse response to the AAV/Cas9 treatment. Additionally, there is reduction of regions of 
necrotic fibers. Scale bars = 600 μm in full-view images and 100 μm in high-power images. 
(d) Significant improvement in specific twitch force (Pt) and tetanic force (Po) as measured 
by an in situ contractility assay in Cas9/gRNA-treated muscles. Treated muscles also 
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showed significantly better resistance to damage caused by repeated cycles of eccentric 
contraction (n=7, mean+s.e.m). Overall treatment effect by ANOVA (p<0.05). Asterisk, 
significantly different from the sham group (p<0.05).
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Figure 4. Systemic delivery of CRISPR/Cas9 by intravenous injection restores dystrophin 
expression in adult mdx mouse cardiac muscle
(a) PCR across the deletion region in the genomic DNA from cardiac tissues shows the 
smaller deletion PCR product in all treated mice. (b) RT-PCR across exons 22 and 24 of 
dystrophin cDNA from cardiac tissue shows a smaller band that does not included exon 23 
in treated mice. (c) Western blot for dystrophin in protein lysates from cardiac tissue shows 
recovery of dystrophin expression (+, AAV injected mice; −, saline injected controls). (d) 
Dystrophin immunofluorescence staining shows dystrophin recovery in cardiomyocytes. 
Scale bar = 100μm
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